Safety of posaconazole

Expert Opinion on Drug Safety

Volumn 12, Issue 2, 2013, Pages 265-274

  Jacinto, Pauline L ^a   Chandrasekar, Pranatharthi ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug interaction; Posaconazole; Safety of azoles

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; BENZODIAZEPINE DERIVATIVE; BILIRUBIN; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450 3A4; EFAVIRENZ; ESOMEPRAZOLE; FOSAMPRENAVIR; ITRACONAZOLE; LIVER ENZYME; METOCLOPRAMIDE; MULTIDRUG RESISTANCE PROTEIN; PANCREAS ENZYME; PHENYTOIN; PIMOZIDE; PLACEBO; POSACONAZOLE; QUINIDINE; RAPAMYCIN; RIFABUTIN; SIMVASTATIN; TACROLIMUS; UNINDEXED DRUG; URIDINE DIPHOSPHATE; VORICONAZOLE;

ABDOMINAL PAIN; ANOREXIA; ANTIBIOTIC PROPHYLAXIS; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL TRIAL (TOPIC); DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG GLUCURONIDATION; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; EYE PAIN; FLU LIKE SYNDROME; FUSARIOSIS; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEARING IMPAIRMENT; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HUMAN; INSOMNIA; INVASIVE ASPERGILLOSIS; KIDNEY FAILURE; LACTATION; LEUKOPENIA; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OROPHARYNX CANDIDIASIS; PERIPHERAL NEUROPATHY; PREGNANCY; QT PROLONGATION; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC MYCOSIS; TORSADE DES POINTES; VISUAL DISORDER; VOMITING;

ANIMALS; ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG INTERACTIONS; HISTAMINE H2 ANTAGONISTS; HUMANS; MYCOSES; NAUSEA; PROTON PUMP INHIBITORS; TRIAZOLES;

EID: 84874133104     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.765857     Document Type: Article

References (58)

1. Walsh T J, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004;10(1):48-66 (Pubitemid 38379951)
2. Miceli M H, Di'az J A, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011;11(2):142-51
3. Miceli M H, Lee SA. Emerging moulds: Epidemiological trends and antifungal resistance. Mycoses 2011;54(6):e666-78
4. Pasqualotto A C, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008;61(1):19-30
5. Mohr J, Johnson M, Cooper T, et al. Current options in antifungal pharmacotherapy. Pharmacotherapy 2008;28(5):614-45 (Pubitemid 351620030)
6. Kathiravan M K, Salake A B, Chothe AS, et al. The biology and chemistry of antifungal agents: B review. Bioorg Med Chem 2012;20(19):5678-98
7. Lestner J M, Roberts S A, Moore CB, et al. Toxicodynamics of itraconazole: Implications for therapeutic drug monitoring. Clin Infect Dis 2009;49(6):928-30
8. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45(7):649-63 (Pubitemid 43990568)
9. Keating GM. Posaconazole. Drugs 2005;65:1553-67 (Pubitemid 41124308)
10. Schering-Plough. Schering-plough announces FDA approval of NOXAFIL(R) (posaconazole) for prevention of invasive fungal infections [News release]. Schering-Plough, Summit NJ; 2006
11. Schiller D S, Fung HB. Posaconazole: Bn extended-spectrum triazole antifungal agent. Clin Ther 2007;29(9):1862-86 (Pubitemid 350212806)
12. Vehreschild J J, Birtel A, Vehreschild MJ, et al. Mucormycosis treated with posaconazole: Review of 96 case reports. Crit Rev Microbiol 2012; [Epub ahead of print
13. Sabatelli F, Patel R, Mann P A, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50(6):2009-15 (Pubitemid 43807519)
14. Koltin Y, Hitchcock CA. The search for new triazole antifungal agents. Curr Opin Chem Biol 1997;1(2):176-82 (Pubitemid 127437142)
15. Krishna G, Ma L, Martinho M, et al. A new solid oral tablet formulation of posaconazole: B randomized clinical trial to investigate rising single- And multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother 2012;67(11):2725-30
16. Li Y, Theuretzbacher U, Clancy CJ, et al. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet 2010;49(6):379-96
17. Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: Evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther 2009;34(3):301-11
18. Cornely O A, Maertens J, Winston DJ, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356(4):348-59 (Pubitemid 46148777)
19. Hachem R Y, Langston A A, Graybill JR, et al. Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. J Antimicrob Chemother 2008;62(6):1386-91
20. Alexander B D, Perfect J R, Daly J S, et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008;86(6):791-6
21. Walsh T J, Raad I, Patterson T F, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: Bn externally controlled trial. Clin Infect Dis 2007;44(1):2-12 (Pubitemid 44968977)
22. Raad I I, Graybill J R, Bustamante AB, et al. Safety of long-Term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42(12):1726-34 (Pubitemid 43839438)
23. Raad I I, Hachem R Y, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42(10):1398-403
24. Felton T W, Baxter C, Moore C B, et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 2010;51(12):1383-91
25. Winston D J, Bartoni K, Territo MC, et al. Efficacy, safety, and breakthrough infections associated with standard long-Term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011;17(4):507-15
26. Skiest D J, Vazquez J A, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007;44(4):607-14 (Pubitemid 46233269)
27. Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005;45(2):185-92 (Pubitemid 40490442)
28. Moton A, Krishna G, Ma L, et al. Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment. Curr Med Res Opin 2010;26(1):1-7
29. Lin S Y, Lu P L, Tsai K B, et al. A mucormycosis case in a cirrhotic patient successfully treated with posaconazole and review of published literature. Mycopathologia 2012;174(5-6):499-504
30. Imhof A, Schaer D J, Schanz U, et al. Neurological adverse events to voriconazole: Evidence for therapeutic drug monitoring. Swiss Med Wkly 2006;136(45-46):739-42 (Pubitemid 46032197)
31. Baxter C G, Marshall A, Roberts M, et al. Peripheral neuropathy in patients on long-Term triazole antifungal therapy. J Antimicrob Chemother 2011;66(9):2136-9
32. Moudgal V V, Sobel JD. Antifungal drugs in pregnancy: B review. Expert Opin Drug Saf 2003;2(5):475-83
33. Food and Drug Administration. Fed Regist 1980;44:37434-67
34. Schering Corp. Package insert: Noxafil. 2011
35. Neofytos D, Avdic E, Magiorakos AP. Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections. Drug Health Patient Saf 2010;2:27-38
36. Sandherr M, Maschmeyer G. Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis: Review of the literature. Eur J Med Res 2011;16(4):139-44
37. Lipp HP. Posaconazole: Clinical pharmacokinetics and drug interactions. Mycoses 2011;54(SUPPL1):32-8
38. Krishna G, Sansone-Parsons A, Kantesaria B. Assessment following concomitant administration of posaconazole and phenytoin in healthy men. Drug Interact Curr Med Res Opin 2007;23(6):1415-22 (Pubitemid 46998449)
39. Krishna G, Parsons A, Kantesaria B, et al. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-Administration to healthy men. Curr Med Res Opin 2007;23(3):545-52 (Pubitemid 46456902)
40. Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr 2009;51(4):437-44
41. Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53(3):958-66
42. Walravens J, Brouwers J, Spriet I, et al. Effect of pH and comedication on gastrointestinal absorption of posaconazole: Monitoring of intraluminal and plasma drug concentrations. Clin Pharmacokinet 2011;50(11):725-34
43. Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004;48(3):804-8 (Pubitemid 38280328)
44. Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007;27(6):825-34 (Pubitemid 46849426)
45. Berge M, Chevalier P, Benammar M, et al. Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis. Ther Drug Monit 2009;31(3):396-9
46. Moton A, Ma L, Krishna G, et al. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin 2009;25(3):701-7
47. Kubiak D W, Koo S, Hammond SP, et al. Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants. Biol Blood Marrow Transplant 2012;18(9):1462-5
48. Poluzzi E, Raschi E, Motola D, et al. Antimicrobials and the risk of torsades de pointes: The contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 2010;33(4):303-14
49. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350(10):1013-22 (Pubitemid 38269278)
50. Krishna G, Ma L, Prasad P, et al. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. Expert Opin Drug Metab Toxicol 2012;8(1):1-10
51. Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 2010;30(8):842-54
52. Moriyama B, Henning S A, Leung J, et al. Adverse interactions between antifungal azoles and vincristine: Review and analysis of cases. Mycoses 2012;55(4):290-7
53. Cronin S, Chandrasekar PH. Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother 2010;65(3):410-16
54. Hussaini T, Rüping M J, Farowski F, et al. Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy 2011;31(2):214-25
55. Dolton M J, Ray J E, Marriott D, et al. Posaconazole exposure-response relationship: Evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012;56(6):2806-13
56. Goodwin M L, Drew RH. Antifungal serum concentration monitoring: Bn update. J Antimicrob Chemother 2008;61(1):17-25
57. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: Established and emerging indications. Antimicrob Agents Chemother 2009;53(1):24-34
58. Dolton M J, Ray J E, Chen S C, et al. A multi-center study of posaconazole therapeutic drug monitoring: Exposure-response and factors affecting concentration. Antimicrob Agents Chemother 2012;56(11):5503-10